Pembrolizumab and cabozantinib in recurrent and/or metastatic head and neck squamous cell carcinoma (RMHNSCC): long-term survival update with a biomarker analysis.
Nabil F SabaRitu ChaudharyKedar S KirtaneAngelo MarraAsari EkpenyongAshley Alesia McCookNicole C SchmittJennifer H GrossMihir R PatelJill RemickJames E BatesMark W McDonaldSoumon F RudraWilliam A StokesMaria I PooleXiaofei SongRobbert J C SlebosYuan LiuConor E SteuerDong M ShinYong TengChristine H ChungPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Pembrolizumab and cabozantinib provided prolonged encouraging long-term disease control and survival with a maintained favorable safety profile. The prognostic significance of increased CD8+, CD103+ and CSF1-R+ cell density in TIME deserve further evaluation in similar clinical settings.